{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T11:17:03Z","timestamp":1795000623945,"version":"4.9.1"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec id=\"ab-eoi240031-4\"><jats:title>Importance<\/jats:title><jats:p>The Diabetic Retinopathy Clinical Research Network Protocol S suggested that vitrectomy for vitreous hemorrhage (VH) or tractional retinal detachment (TRD) was more common among eyes assigned initially to panretinal photocoagulation (PRP) vs anti\u2013vascular endothelial growth factor (anti-VEGF) for proliferative diabetic retinopathy (PDR). These clinical implications warrant further evaluation in the clinical practice setting.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240031-5\"><jats:title>Objective<\/jats:title><jats:p>To explore outcomes of PDR treated with PRP monotherapy compared with matched patients treated with anti-VEGF monotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240031-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Retrospective cohort study using an aggregated electronic health records research network. Patients with PDR who received PRP or anti-VEGF monotherapy between January and September 2023 were included before propensity score matching. Patients were excluded with 6 or fewer months\u2019 follow-up after monotherapy or with a combination of PRP and anti-VEGF. Data were analyzed in September 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240031-7\"><jats:title>Exposures<\/jats:title><jats:p>Patients with new PDR diagnoses stratified by monotherapy with PRP or anti-VEGF agents using <jats:italic>Current Procedural Terminology<\/jats:italic> code.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240031-8\"><jats:title>Main Outcome Measures<\/jats:title><jats:p>Incidence of pars plana vitrectomy (PPV), VH, or TRD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240031-9\"><jats:title>Results<\/jats:title><jats:p>Among 6020 patients (PRP cohort: mean [SD] age, 64.8 [13.4]; 6424 [50.88%] female; 3562 [28.21%] Black, 6180 [48.95%] White, and 2716 [21.51%] unknown race; anti-VEGF cohort: mean [SD] age, 66.1 [13.2]; 5399 [50.52%] male; 2859 [26.75%] Black, 5377 [50.31%] White, and 2382 [22.29%] unknown race) who received treatment, PRP monotherapy was associated with higher rates of PPV when compared with patients treated with anti-VEGF monotherapy at 5 years (RR, 1.18; 95% CI, 1.05-1.36; RD, 1.37%; 95% CI, 0.39%-2.37%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), with similar associations at 1 and 3 years. PRP monotherapy was  associated with higher rates of VH at 5 years (relative risk [RR], 1.72; 95% CI, 1.52-1.95; risk difference [RD], 7.05; 95% CI, 5.41%-8.69%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and higher rates of TRD at 5 years (RR, 2.76; 95% CI, 2.26-3.37; RD, 4.25%; 95% CI, 3.45%-5.05%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), with similar magnitudes of associations at 6 months, 1 year, and 3 years, when compared with patients treated with anti-VEGF monotherapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi240031-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings support the hypothesis that patients with PDR treated with PRP monotherapy are more likely to develop VH, TRD, and undergo PPV when compared with matched patients treated with anti-VEGF monotherapy. However, given the wide range in relative risk, confounding factors may account for some of the association between PRP vs anti-VEGF monotherapy and outcomes evaluated.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.1844","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:33:04Z","timestamp":1717687984000},"page":"662","source":"Crossref","is-referenced-by-count":18,"title":["Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy"],"prefix":"10.1001","volume":"142","author":[{"given":"Amer F.","family":"Alsoudi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Wai","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euna","family":"Koo","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Parikh","sequence":"additional","affiliation":[{"name":"Manhattan Retina and Eye Consultants, New York, New York"},{"name":"New York University Langone Health, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California"},{"name":"Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"eoi240031r1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss.","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"issue":"10","key":"eoi240031r2","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi240031r3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0161-6420(87)33527-4","article-title":"Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: early treatment diabetic retinopathy study report number 2.","volume":"94","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1987","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi240031r4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","article-title":"Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients.","volume":"124","author":"Parikh","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi240031r5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.oret.2020.10.002","article-title":"Trends in anti-vascular endothelial growth factor agents and panretinal photocoagulation use in diabetic retinopathy.","volume":"5","author":"Azad","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"eoi240031r6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.oret.2020.07.018","article-title":"Anti-vascular endothelial growth factor and panretinal photocoagulation use after protocol S for proliferative diabetic retinopathy.","volume":"5","author":"Azad","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"eoi240031r7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oret.2018.08.002","article-title":"A multinational comparison of anti-vascular endothelial growth factor use: the United States, the United Kingdom, and Asia-Pacific.","volume":"3","author":"Parikh","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"eoi240031r8","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.ophtha.2016.05.037","article-title":"Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy.","volume":"123","author":"Lin","year":"2016","journal-title":"Ophthalmology"},{"issue":"20","key":"eoi240031r9","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"eoi240031r10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"eoi240031r11","first-page":"2202","article-title":"Vitrectomy after anti-VEGF or pan-retinal photocoagulation therapy in proliferative diabetic retinopathy.","volume":"63","author":"Hwang","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"eoi240031r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"4","key":"eoi240031r13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy.","volume":"81","author":"The Diabetic Retinopathy Study Research Group","year":"1976","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi240031r14","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9.","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"10085","key":"eoi240031r15","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"eoi240031r16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2011.05.035","article-title":"Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser.","volume":"153","author":"Chappelow","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"eoi240031r17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/IAE.0b013e318042d32c","article-title":"Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review.","volume":"27","author":"Fong","year":"2007","journal-title":"Retina"},{"issue":"3","key":"eoi240031r18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor.","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"key":"eoi240031r19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.09.051","article-title":"Impact and characterization of delayed pan-retinal photocoagulation in proliferative diabetic retinopathy.","volume":"223","author":"Ohlhausen","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi240031r20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study).","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi240031r24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaophthalmol.2019.5939","article-title":"Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy.","volume":"138","author":"Maguire","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"eoi240031r25","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamaophthalmol.2019.4284","article-title":"Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial.","volume":"137","author":"Hutton","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"eoi240031r21","unstructured":"Singh? RP. ASRS global trends in retina. 2018. Accessed October 29, 2023. https:\/\/www.asrs.org\/content\/documents\/2018-global-trends-in-retina-survey-highlights-website.pdf"},{"key":"eoi240031r22","unstructured":"Singh? RP. ASRS global trends in retina. 2019. Accessed October 29, 2023. https:\/\/www.asrs.org\/content\/documents\/2019-global-trends-survey-for-website.pdf"},{"key":"eoi240031r23","unstructured":"The American Society of Retina Specialists. Preferences and trends (PAT) survey. Accessed October 29, 2023. https:\/\/www.asrs.org\/asrs-community\/pat-survey"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2819800\/jamaophthalmology_alsoudi_2024_oi_240031_1719935946.96052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:04:01Z","timestamp":1721315041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2819800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.1844","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}